A broad-spectrum macrocyclic peptide inhibitor of the SARS-CoV-2 spike protein

The ongoing COVID-19 pandemic has had great societal and health consequences. Despite the availability of vaccines, infection rates remain high due to immune evasive Omicron sublineages. Broad-spectrum antivirals are needed to safeguard against emerging variants and future pandemics. We used mRNA display under a reprogrammed genetic code to find a spike-targeting macrocyclic peptide that inhibits SARS-CoV-2 Wuhan strain infection and pseudoviruses containing spike proteins of SARS-CoV-2 variants or related sarbecoviruses. Structural and bioinformatic analyses reveal a conserved binding pocket between the receptor binding domain, N-terminal domain and S2 region, distal to the ACE2 receptor-interaction site. Our data reveal a hitherto unexplored site of vulnerability in sarbecoviruses that peptides and potentially other drug-like molecules can target. Significance statement This study reports on the discovery of a macrocyclic peptide that is able to inhibit SARS-CoV-2 infection by exploiting a new vulnerable site in the spike glycoprotein. This region is highly conserved across SARS-CoV-2 variants and the subgenus sarbecovirus. Due to the inaccessability and mutational contraint of this site, it is anticipated to be resistant to the development of resistance through antibody selective pressure. In addition to the discovery of a new molecule for development of potential new peptide or biomolecule therapeutics, the discovery of this broadly active conserved site can also stimulate a new direction of drug development, which together may prevent future outbreaks of related viruses.

[1]  V. Hu,et al.  The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations , 2022, Medicinal Chemistry Research.

[2]  Fei Shao,et al.  BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection , 2022 .

[3]  Fa-Jie Chen,et al.  Lysine-Targeted Reversible Covalent Ligand Discovery for Proteins via Phage Display. , 2022, Journal of the American Chemical Society.

[4]  Fei Shao,et al.  Characterizations of enhanced infectivity and antibody evasion of Omicron BA.2.75 , 2022, bioRxiv.

[5]  A. Gruber,et al.  The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variants , 2022, Nature biotechnology.

[6]  G. Pantaleo,et al.  Antibodies to combat viral infections: development strategies and progress , 2022, Nature Reviews Drug Discovery.

[7]  Fei Shao,et al.  BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection , 2022, Nature.

[8]  F. Grosveld,et al.  An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants of concern , 2022, bioRxiv.

[9]  P. Maes,et al.  Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralization , 2021, bioRxiv.

[10]  M. Diamond,et al.  Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail , 2021, Nature Microbiology.

[11]  H. Suga,et al.  The RaPID Platform for the Discovery of Pseudo-Natural Macrocyclic Peptides. , 2021, Accounts of chemical research.

[12]  D. Sellers,et al.  Discovery and Characterization of Spike N‐Terminal Domain‐Binding Aptamers for Rapid SARS‐CoV‐2 Detection , 2021, Angewandte Chemie.

[13]  M. Beltramello,et al.  SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape , 2021, Nature.

[14]  D. Sheward,et al.  A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo , 2021, bioRxiv.

[15]  M. Natchus,et al.  Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19 , 2021, Current Opinion in Virology.

[16]  L. Purcell,et al.  Tackling COVID-19 with neutralizing monoclonal antibodies , 2021, Cell.

[17]  Nichollas E. Scott,et al.  Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice , 2021, Proceedings of the National Academy of Sciences.

[18]  Honglin Chen,et al.  Aptamer Blocking Strategy Inhibits SARS‐CoV‐2 Virus Infection , 2021, Angewandte Chemie.

[19]  Lisa E. Gralinski,et al.  Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody , 2021, Science.

[20]  Chao Zhang,et al.  Conformational dynamics of SARS-CoV-2 trimeric spike glycoprotein in complex with receptor ACE2 revealed by cryo-EM , 2020, Science Advances.

[21]  S. Ferrari,et al.  Author contributions , 2021 .

[22]  J. Mackay,et al.  Discovery of Cyclic Peptide Ligands to the SARS-CoV-2 Spike Protein Using mRNA Display , 2020, bioRxiv.

[23]  S. Pomplun.  Targeting the SARS-CoV-2-spike protein: from antibodies to miniproteins and peptides , 2020, RSC medicinal chemistry.

[24]  D. Schneidman-Duhovny,et al.  Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2 , 2020, Science.

[25]  N. Krogan,et al.  An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike , 2020, Science.

[26]  Genwei Zhang,et al.  De Novo Discovery of High-Affinity Peptide Binders for the SARS-CoV-2 Spike Protein , 2020, bioRxiv.

[27]  D. Baker,et al.  De novo design of picomolar SARS-CoV-2 miniprotein inhibitors , 2020, bioRxiv.

[28]  R. Owens,et al.  Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2 , 2020, Nature Structural & Molecular Biology.

[29]  D. Svergun,et al.  Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2 , 2020, Nature Communications.

[30]  D. Sheward,et al.  An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interaction , 2020, Nature Communications.

[31]  M. Beltramello,et al.  Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody , 2020, Nature.

[32]  Amalio Telenti,et al.  Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody , 2020, Nature.

[33]  Shaun Rawson,et al.  Distinct conformational states of SARS-CoV-2 spike protein , 2020, Science.

[34]  M. Hall,et al.  Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19 , 2020, ACS central science.

[35]  Yanling Song,et al.  Discovery of Aptamers Targeting the Receptor-Binding Domain of the SARS-CoV-2 Spike Glycoprotein , 2020, Analytical chemistry.

[36]  Linqi Zhang,et al.  Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor , 2020, Nature.

[37]  N. Callewaert,et al.  Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies , 2020, Cell.

[38]  B. Graham,et al.  Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.

[39]  M. Defrise,et al.  Size and affinity kinetics of nanobodies influence targeting and penetration of solid tumours. , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[40]  H. Suga,et al.  Macrocyclic Peptides as Drug Candidates: Recent Progress and Remaining Challenges. , 2019, Journal of the American Chemical Society.

[41]  J. Rossi,et al.  Aptamers as targeted therapeutics: current potential and challenges , 2016, Nature Reviews Drug Discovery.

[42]  B. Bosch,et al.  The Coronavirus Spike Protein Is a Class I Virus Fusion Protein: Structural and Functional Characterization of the Fusion Core Complex , 2003, Journal of Virology.